Medication-info.com Search Menu

Fem pH (Acetic acid and Oxyquinoline sulfate) Package Insert

Status:
Prescription (Rx) Facts
Strength:
0.009 g/g, 0.00025 g/g
Other brand names:
  • Relagard
Active ingredients:

Prescribing information (package insert) - Fem pH

Rx Only

Description

Fem pH Vaginal Jelly is a bland, non-irritating water dispersible, buffered acid jelly for intravaginal use. Fem pH is classified as a Vaginal Therapeutic Jelly. Fem pH contains 0.9% glacial acetic acid (C2H402) and 0.025% oxyquinoline sulfate (C18H16N206S) compounded with glycerin, lactic acid, poly ethylene glycol 4500 and purified water. Fem pH is formulated to pH 3.8-4.3 and is adjusted using 1 N potassium hydroxide.

Clinical Pharmacology

Fem pH acts to restore and maintain normal vaginal acidity through its buffered action.

Indications and Usage

Fem pH is indicated as adjunctive therapy in those cases where restoration and maintenance of vaginal acidity is desirable.

Contraindications

None known.

Warnings

No serious adverse reactions or potential safety hazard have been reported with the use of Fem pH .

Precautions

General

No special care is required for the safe and effective use of Fem pH .

Drug Interactions

No incidence of drug interactions has been reported with concomitant use of Fem pH and any other medication.

Laboratory Tests

The monitoring of vaginal acidity (pH) may be helpful in following the patient's response. (The normal vaginal pH has been shown to be in the range of 4.0 to 5.0)

Carcinogenesis

No long-term studies in animals have been performed to evaluate carcinogenic potential.

Pregnancy

Pregnancy Category C

Animal reproduction studies have not been conducted with Fem pH . It is not known whether Fem pH can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Fem pH should be given to a pregnant woman only if clearly needed.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Fem pH is administered to a nursing woman.

Adverse Reactions

Occasional cases of local stinging and burning have been reported.

Dosage and Administration

The usual dose is one applicator full, administered intra-vaginally, morning and evening. Duration of treatment may be determined by the patient's response to therapy. Each tube has a tamper evident seal at the opening of the tube. Replace cap after each use. To fill applicator screw applicator clockwise onto the tube. Squeeze tube forcing Fem pH jelly into barrel until it is full. Then unscrew applicator counter-clockwise to remove from tube. Lie on your back with knees drawn up. Hold filled applicator by the barrel and gently insert it into the vagina as far as it will comfortably go. Press plunger to empty the contents. Keep the plunger depressed and remove the applicator from vagina. After each use pull applicator apart and wash with warm soapy water, rinse well, dry and reassemble.

How Supplied

50g Tube (NDC 00813-0799-55) with Fem pH applicator.

Keep this and all medication out of the reach of children. In case of accidental overdose, call a doctor or poison control center immediately.

Store at controlled room temperature 59°-86°F (15°-30°C)

About this document

Source: FDA drug labeling via NLM DailyMed · View the label on DailyMed

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Fem pH

Rx or OTC
Prescription (Rx)?
  • This drug is available only with a prescription from a licensed healthcare provider.
  • Rx
Active ingredients Acetic acid 0.009 g/g, Oxyquinoline sulfate 0.0003 g/g
Dosage form Jelly
Route Vaginal
Marketing status not in the current FDA NDC Directory
Company (applicant) Pharmics, Inc.
FDA approval UNAPPROVED DRUG OTHERUnapproved drug
Manufacturers 1 labelers list this drug on DailyMed
Packages (NDC)
Package
0.009 g/g, 0.00025 g/g – 50 g in 1 tube NDC 0813-0799-55

Source: FDA drug labeling via NLM DailyMed, data as of October 31, 2026. FDA data (DailyMed, Orange Book, Drug Shortages, enforcement reports). Not a substitute for the advice of a doctor or pharmacist.